- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02875821
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
Study Overview
Status
Intervention / Treatment
Detailed Description
Pioglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist increase insulin sensitivity in peripheral tissue and liver by protecting non-adipose tissues against excessive lipid overload and by balancing the secretion of adipocytokines.
However, PPARγ is a key transcription factor that induces the differentiation adipocyte maturation and stimulates the induction of enzymes involved in lipogenesis. As a result, the effect of pioglitazone is generally accompanied by weight gain and an increase in amount of subcutaneous fat.
Obesity would coexist with fatty liver disease and both conditions aggravate hyperglycemia in diabetes. According to recent study, up-regulated PPARγ expression in liver was reported in obesity with hepatic steatosis which implies pioglitazone might induce fatty liver disease.
A novel oral antidiabetic drug, sodium glucose cotransporter 2 (SGLT2) inhibitor reduces renal glucose reabsorption and increasing renal glucose excretion thereby promoting energy loss. As a result, it prevents weight gain and fluid retention which might counteract the unfavorable effects of pioglitazone treatment.
No study has been conducted on the additional effect on obesity and fatty liver of ipragliflozin in T2DM patients treated with pioglitazone and metformin.
In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and pioglitazone therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetic patients
- Diagnosed as NAFLD
- Age of 20~75
- On metformin + pioglitazone treatment with stable dose for at least 8 weeks
- Adequate glycemic control: HbA1c ≤ 9.5%
- Overweight & obese: BMI ≥ 23 kg/m2
- Subject is male, or subject is female who is highly unlikely to conceive
- Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed consent
Exclusion Criteria:
- Type 1 diabetes, Secondary diabetes, gestational diabetes
- Heavy alcoholics (men ≥210 g of alcohol per week, women ≥140 g of alcohol per week)
- Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis [except hepatitis B carrier], Wilson's disease)
- Patients on medication causes hepatic steatosis (e.g.amiodarone, methotrexate, tamoxifen, valproate, corticosteroids, etc)
- Allergy or hypersensitivity to target medication or any of its components
- Renal failure, moderate or severe renal impairment (estimated glomerular filtration rate < 60 mL/min/1.73 m2), or ongoing dialysis
- Abnormal liver function (AST/ALT > x10 upper normal limit)
- On taking weight loss medication
- History of alcohol or drug abuse in the previous 3 months
- Premenopausal women who are nursing or pregnant
- Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS)
- Diabetic ketoacidosis
- Severe infection, severe trauma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group IMP
Group IMP (Ipragliflozin with Metformin with Pioglitazone)
|
Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months.
During whole periods of study, subjects are educated for nutrition and exercise.
(Experimental Group)
Other Names:
|
Active Comparator: Group MP
Group MP (Metformin with Pioglitazone)
|
Patients maintain metformin and pioglitazone dual therapy for 6 months.
During whole periods of study, subjects are educated for nutrition and exercise.
(Control group)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in visceral fat area
Time Frame: 6 months
|
The visceral fat area is measured by dual-energy x-ray absorptiometry (DEXA) at baseline and after 6 months treatment
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in subcutaneous fat area
Time Frame: 6 months after treatment
|
The subcutaneous fat area is measured by dual-energy x-ray absorptiometry (DEXA) and fat computed tomography (CT) at baseline and after 6 months treatment.
|
6 months after treatment
|
Changes in liver fat
Time Frame: 6 months after treatment
|
Changes in the degree of fatty liver is measured by fibroscan using controlled attenuation parameter (CAP) score.
|
6 months after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Liver Diseases
- Diabetes Mellitus, Type 2
- Fatty Liver
- Non-alcoholic Fatty Liver Disease
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Metformin
- Pioglitazone
- Ipragliflozin
Other Study ID Numbers
- 4-2015-1115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
-
The Deutsche Diabetes Forschungsgesellschaft e.V.Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaboratorsRecruitingType 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)Germany, Austria
-
University of AarhusDanish Diabetes AcademyCompletedType 2 Diabetes | NAFLD - Non-Alcoholic Fatty Liver DiseaseDenmark
-
Ann & Robert H Lurie Children's Hospital of ChicagoNot yet recruitingNAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLDUnited States
-
University of FloridaInventiva PharmaCompletedNonalcoholic Fatty Liver Disease (NAFLD) | Type 2 Diabetes (T2DM)United States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
AstraZenecaCompleted
-
Pichamol Jirapinyo, MD, MPHNot yet recruitingLiver Diseases | Metabolic Diseases | Obesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Insulin Resistance | Weight Loss | Liver Fat | NAFLD | Insulin Sensitivity/Resistance | Insulin Sensitivity | Liver Fibrosis | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non Alcoholic Fatty... and other conditionsUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
HighTide Biopharma Pty LtdCompletedDigestive System Diseases | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Type 2 Diabetes Mellitus (T2DM) | Fatty Liver, NonalcoholicUnited States
Clinical Trials on Ipragliflozin
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration of ASP1941Japan
-
Astellas Pharma IncCompletedA Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941Healthy | Pharmacokinetics of ASP1941Japan
-
Astellas Pharma IncCompletedType 2 Diabetes MellitusUnited States, Hungary, Poland, Romania, Italy, United Kingdom
-
Astellas Pharma IncCompletedType 2 Diabetes MellitusJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedType 2 Diabetes MellitusJapan
-
Astellas Pharma IncAstellas Pharma Taiwan, Inc.CompletedHealthy | Pharmacokinetics of ASP1941Taiwan
-
Astellas Pharma IncCompletedType 2 Diabetes MellitusJapan
-
Astellas Pharma IncCompletedDiabetes Mellitus, Type 2United States, India, Philippines, Colombia, Mexico
-
Astellas Pharma Korea, Inc.CompletedType 2 Diabetes MellitusKorea, Republic of